{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:29:11Z","timestamp":1793644151527,"version":"4.5.1"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Long-acting drugs were recently introduced for HIV treatment, so there are no medium-term or long-term data in real-world settings. Aims were to assess the cumulative probability of treatment discontinuation and the proportion of people with HIV (PWH) with HIV RNA less than 50\u200acopies\/ml at month 24 among participants switching to cabotegravir (CAB) and rilpivirine (RPV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>SCohoLART is a single-center, prospective, cohort study enrolling PWH on virological suppression who switched to bimonthly long-acting CAB\/RPV.<\/jats:p>\n                    <jats:p>Treatment discontinuation occurred at switch to another regimen for any reason including virological failure; virological failure was defined as HIV RNA at least 50\u200acopies\/ml at two consecutive measurements or a single HIV RNA at least 1000\u200acopies\/ml. Participants\u2019 characteristics were reported as median (interquartile range, IQR) or frequency (%). Cumulative probabilities of TD were estimated by Kaplan\u2013Meier curve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>We evaluated 549 participants: 501 (91.3%) were men and median age was 49 (40\u201356). At the time of switching, median years from HIV diagnosis and of ART were 13.8 (8.7\u201320.4) and 11.3 (7.9\u201317.3).<\/jats:p>\n                    <jats:p>During a median follow-up of 24.0 (17.0\u201326.8) months, 86 PWH experienced treatment discontinuations (15.6%), including 6 (1.1%) for virological failure, 37 (6.7%) for injection site reactions (ISRs) and 17 (3.1%) for lifestyle changes incompatible with administrations. The cumulative probabilities of treatment discontinuation were 10.5% at month 12 and 16.4% at month 24.<\/jats:p>\n                    <jats:p>The proportions of participants with HIV RNA less than 50\u200acopies\/ml at months 12 and 24 were 99.0 and 98.6%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>CAB\/RPV demonstrated high virological efficacy over 2 years in a real-world setting; ISRs represented the leading cause of discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/qad.0000000000004591","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:00:41Z","timestamp":1786006841000},"page":"1836-1841","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Two-year efficacy and safety of long-acting cabotegravir and rilpivirine in the SCohoLART study"],"prefix":"10.1097","volume":"40","author":[{"given":"Camilla","family":"Muccini","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2","family":"Capra","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Lolatto","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Spagnuolo","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Canetti","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bossolasco","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Bagaglio","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Loi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Striglia","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"},{"name":"Vita-Salute San Raffaele University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, IRCCS San Raffaele Scientific Institute"},{"name":"Vita-Salute San Raffaele University, Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"R1-20261102","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkab324","article-title":"Long-acting antiretrovirals: a new era for the management and prevention of HIV infection","volume":"77","author":"Thoueille","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"R2-20261102","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","author":"Nachega","year":"2023","journal-title":"Lancet HIV"},{"key":"R3-20261102","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","article-title":"Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection","volume":"382","author":"Orkin","year":"2020","journal-title":"N Engl J Med"},{"key":"R4-20261102","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/S0140-6736(20)32666-0","article-title":"Long-acting cabotegravir and rilpivirine dosed every 2\u200amonths in adults with HIV-1 infection (ATLAS-2\u200aM), 48-week results: a randomised, multicentre, open-label, phase 3b, noninferiority study","volume":"396","author":"Overton","year":"2021","journal-title":"Lancet"},{"key":"R5-20261102","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S2352-3018(23)00136-4","article-title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, noninferiority trial","volume":"10","author":"Ramgopal","year":"2023","journal-title":"Lancet HIV"},{"key":"R6-20261102","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jac\/dkaf025","article-title":"Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV","volume":"80","author":"Taramasso","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"R7-20261102","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000003984","article-title":"CD4+\/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine","volume":"38","author":"Muccini","year":"2024","journal-title":"AIDS"},{"key":"R8-20261102","doi-asserted-by":"crossref","first-page":"ofae326","DOI":"10.1093\/ofid\/ofae326","article-title":"One year of long-acting cabotegravir and rilpivirine in people with human immunodeficiency virus and long exposure to antiretroviral therapy: data from the SCohoLART Study","volume":"11","author":"Muccini","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"R9-20261102","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"R10-20261102","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/QAD.0000000000003025","article-title":"Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment","volume":"36","author":"Swindells","year":"2022","journal-title":"AIDS"},{"key":"R11-20261102","doi-asserted-by":"crossref","first-page":"ofab439","DOI":"10.1093\/ofid\/ofab439","article-title":"Efficacy, safety, and durability of long-acting cabotegravir and rilpivirine in adults with human immunodeficiency virus type 1 infection: 5-year results from the LATTE-2 Study","volume":"8","author":"Smith","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"R12-20261102","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/hiv.13647","article-title":"Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)","volume":"25","author":"John","year":"2024","journal-title":"HIV Med"},{"key":"R13-20261102","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/jac\/dkae308","article-title":"Real-world data on long-acting intramuscular maintenance therapy with cabotegravir and rilpivirine mirror Phase 3 results","volume":"79","author":"Serris","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"R14-20261102","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1007\/s40121-023-00890-2","article-title":"Cabotegravir + rilpivirine long-acting injections for HIV treatment in the US: real world data from the OPERA Cohort","volume":"12","author":"Sension","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R15-20261102","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1016\/S2352-3018(24)00269-8","article-title":"Effectiveness of bi-monthly long-acting injectable cabotegravir and rilpivirine as maintenance treatment for HIV-1 in the Netherlands: results from the Dutch ATHENA national observational cohort","volume":"12","author":"Jongen","year":"2025","journal-title":"Lancet HIV"},{"key":"R16-20261102","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.lanepe.2023.100793","article-title":"Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland","volume":"36","author":"Thoueille","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"R17-20261102","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/jac\/dkaf184","article-title":"Effectiveness and predictors of treatment discontinuations of long-acting cabotegravir\/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona cohort","volume":"80","author":"Gagliardini","year":"2025","journal-title":"J Antimicrob Chemoter"},{"key":"R18-20261102","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1111\/hiv.13679","article-title":"Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics (SHARE LAI-net)","volume":"25","author":"Ring","year":"2024","journal-title":"HIV Med"},{"key":"R19-20261102","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/cid\/ciad370","article-title":"Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virological failure","volume":"77","author":"Orkin","year":"2023","journal-title":"Clin Infect Dis"},{"key":"R20-20261102","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1093\/jac\/dkaf389","article-title":"A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)","volume":"80","author":"Buz\u00f3n-Mart\u00edn","year":"2025","journal-title":"J Antimicrob Chemother"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0000000000004591","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:01:29Z","timestamp":1793642489000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/QAD.0000000000004591"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":20,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0000000000004591","relation":{},"ISSN":["0269-9370","1473-5571"],"issn-type":[{"value":"0269-9370","type":"print"},{"value":"1473-5571","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"assertion":[{"value":"2026-02-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}